GlassScriptPhysician profile
Hunter Alexander Smith
NPI 1548674310
$6,373.03
in general payments reported to CMS, 2019-2025
39 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $456 · 2021: $766 · 2022: $1,323 · 2023: $1,224 · 2024: $1,079 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,338.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,520.76 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Sumitomo Pharma America, INC. | $1,160.69 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $328.65 | 2023-2025 | |
| Exeltis, USA INC. | $328.09 | 2020-2025 | Slynd |
| Hologic Sales and Service, LLC | $312.58 | 2019-2025 | Thinprep 2000 Processor, Aptima, Myosure Tissue Removal Device |
| Sage Therapeutics, LLC | $225.01 | 2021-2025 | Zurzuvae |
| Medtronic USA, INC. | $211.11 | 2019 | |
| Myovant Sciences INC. | $208.15 | 2022 | |
| Channel Medsystems, INC. | $189.93 | 2022-2025 | |
| Organon LLC | $189.53 | 2021-2025 | Nexplanon, Nuvaring |
| Shield Therapeutics INC | $182.67 | 2023-2025 | Accrufer |
| Therapeuticsmd, INC. | $164.53 | 2019-2022 | |
| Millicent US INC | $136.61 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Boston Scientific Corporation | $128.10 | 2020-2024 | |
| Optumhealth Care Solutions, LLC | $116.48 | 2023-2025 | Vivify Health Care Team Portal 001, Eitan Medical, Zyno Solutions |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $112.73 | 2019-2025 | |
| Astellas Pharma US INC | $103.29 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $97.92 | 2019-2020 | |
| Scynexis, INC. | $84.86 | 2022 | |
| Momentis Surgical INC. | $74.00 | 2022 | |
| Mylan Pharmaceuticals INC. | $65.01 | 2021-2022 | |
| Pfizer INC. | $59.61 | 2022-2024 | |
| Avion Pharmaceuticals | $50.58 | 2022 | |
| Agile Therapeutics, INC. | $43.72 | 2021-2023 | Twirla |
| Evofem Biosciences, INC. | $37.85 | 2021 | |
| Minerva Surgical, INC | $33.20 | 2024-2025 | |
| Allergan, INC. | $23.89 | 2019 | |
| Trevena, INC. | $23.66 | 2021 | |
| Meditrina | $22.80 | 2023 | |
| Lupin INC. | $22.73 | 2019-2020 | |
| Exact Sciences Corporation | $18.06 | 2023 | Cologuard Collection Kit |
| Aspira Women'S Health INC | $15.68 | 2022 | |
| Axonics, INC. | $14.98 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.97 | 2021 | |
| Amag Pharmaceuticals, INC. | $13.78 | 2020 | |
| Gynesonics, INC. | $13.74 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Avanos Medical | $12.18 | 2022 | |
| Duchesnay USA Incorporated | $11.90 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.